Literature DB >> 24076085

Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway.

C M Forrest1, O S Khalil, M Pisar, K McNair, E Kornisiuk, M Snitcofsky, N Gonzalez, D Jerusalinsky, L G Darlington, T W Stone.   

Abstract

During early brain development, N-methyl-d-aspartate (NMDA) receptors are involved in cell migration, neuritogenesis, axon guidance and synapse formation, but the mechanisms which regulate NMDA receptor density and function remain unclear. The kynurenine pathway of tryptophan metabolism includes an agonist (quinolinic acid) and an antagonist (kynurenic acid) at NMDA receptors and we have previously shown that inhibition of the pathway using the kynurenine-3-monoxygenase inhibitor Ro61-8048 in late gestation produces rapid changes in protein expression in the embryos and effects on synaptic transmission lasting until postnatal day 21 (P21). The present study sought to determine whether any of these effects are maintained into adulthood. After prenatal injections of Ro61-8048 the litter was allowed to develop to P60 when some offspring were euthanized and the brains removed for examination. Analysis of protein expression by Western blotting revealed significantly reduced expression of the GluN2A subunit (32%) and the morphogenetic protein sonic hedgehog (31%), with a 29% increase in the expression of doublecortin, a protein associated with neurogenesis. No changes were seen in mRNA abundance using quantitative real-time polymerase chain reaction. Neuronal excitability was normal in the CA1 region of hippocampal slices but paired-pulse stimulation revealed less inhibition at short interpulse intervals. The amount of long-term potentiation was decreased by 49% in treated pups and recovery after low-frequency stimulation was delayed. The results not only strengthen the view that basal, constitutive kynurenine metabolism is involved in normal brain development, but also show that changes induced prenatally can affect the brains of adult offspring and those changes are quite different from those seen previously at weaning (P21). Those changes may be mediated by altered expression of NMDAR subunits and sonic hedgehog.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]-benzenesulfonamide; ANOVA; CED; COX-2; Cambridge Electronic Design; DISC-1; Disrupted in Schizophrenia-1; HRP; IDO; KMO; LTD; LTP; N-methyl-d-aspartate; NMDA; P; PCNA; PPF; PPI; PSD-95; Post-Synaptic Density molecule-95; Proliferating Cell Nuclear Antigen; Ro61-8048; TBST; TH; Tris-buffered saline containing 0.05% Tween; VAMP-1; Vesicle-Associated Membrane Protein-1; aCSF; analysis of variance; artificial cerebrospinal fluid; cyclo-oxygenase-2; doublecortin; fEPSP; field excitatory postsynaptic potential; hedgehog; horseradish peroxidase; indoleamine-2,3-dioxygenase; kynurenic acid; kynurenine-3-monoxygenase; kynurenines; long-term depression; long-term potentiation; neurodevelopment; paired-pulse facilitation; paired-pulse inhibition; postnatal day; qt-PCR; quantitative real-time polymerase chain reaction; tryptophan; tyrosine hydroxylase

Mesh:

Substances:

Year:  2013        PMID: 24076085     DOI: 10.1016/j.neuroscience.2013.09.034

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  27 in total

Review 1.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

2.  Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine.

Authors:  Ana Pocivavsek; Greg I Elmer; Robert Schwarcz
Journal:  Hippocampus       Date:  2018-12-04       Impact factor: 3.899

3.  Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.

Authors:  Francesca M Notarangelo; Sarah Beggiato; Robert Schwarcz
Journal:  Dev Neurosci       Date:  2019-05-22       Impact factor: 2.984

Review 4.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

5.  Restraint Stress during Pregnancy Rapidly Raises Kynurenic Acid Levels in Mouse Placenta and Fetal Brain.

Authors:  Francesca M Notarangelo; Robert Schwarcz
Journal:  Dev Neurosci       Date:  2017-02-18       Impact factor: 2.984

6.  Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.

Authors:  Michelle L Pershing; David M Bortz; Ana Pocivavsek; Peter J Fredericks; Christinna V Jørgensen; Sarah A Vunck; Benedetta Leuner; Robert Schwarcz; John P Bruno
Journal:  Neuropharmacology       Date:  2014-11-01       Impact factor: 5.250

Review 7.  The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Authors:  Raeesah Maqsood; Trevor W Stone
Journal:  Neurochem Res       Date:  2016-08-23       Impact factor: 3.996

8.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

9.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

Review 10.  Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Authors:  Francesca M Notarangelo; Ana Pocivavsek
Journal:  Neuropharmacology       Date:  2016-03-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.